The paper analyzes shock treatment with delta-opioid receptor ligands. A reliable pharmacological approach to the prevention of haemodynamic and metabolic irreversibility in shock remains a major problem in critical care. Delta- (and kappa)-opioid agonists have been reported, though not consistently and involving differing mechanism. The administration of low-dose DADLE together with a selective iNOS inhibitor would significantly improve haemorrhagic shock. This pharmacological approach is likely to determine the beneficial effects of a “moderate” delta (delta1)-opioid receptor stimulation on organ preservation without the harmful haemodynamic and metabolic effects of massive NO plasma levels secondary to severe and protracted bowel ischaemia.
Delta-opioid receptor ligands in shock treatment
CARMIGNANI, Marco;VOLPE, ANNA RITA;
2009-01-01
Abstract
The paper analyzes shock treatment with delta-opioid receptor ligands. A reliable pharmacological approach to the prevention of haemodynamic and metabolic irreversibility in shock remains a major problem in critical care. Delta- (and kappa)-opioid agonists have been reported, though not consistently and involving differing mechanism. The administration of low-dose DADLE together with a selective iNOS inhibitor would significantly improve haemorrhagic shock. This pharmacological approach is likely to determine the beneficial effects of a “moderate” delta (delta1)-opioid receptor stimulation on organ preservation without the harmful haemodynamic and metabolic effects of massive NO plasma levels secondary to severe and protracted bowel ischaemia.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.